We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,477

Sandoz v Amgen: An update
  • Bristows
  • USA
  • January 9 2018

In our most recent publication, the Bristows' Biotech Review (Page 3), we reported on the US Supreme Court decision which, at the time, was the latest


The Highs Celebrating the Ten Best Prescription DrugMedical Device Decisions of 2017
  • Reed Smith LLP
  • USA
  • December 28 2017

Ending the year on a high note is one thing that the blog tries to do - with the top ten drugdevice product liability decisions of the year


Guest Post: Christmas Came Early on December 8 - Favorable Developments in Fosamax & Accutane Litigation
  • Reed Smith LLP
  • USA
  • December 14 2017

This guest post is by Kevin Hara, an associate at Reed Smith and relatively frequent contributor to the Blog. Here, he discusses two recent favorable


Forum Non Conveniens and Choice of Law - Issues Post BMS
  • Dechert LLP
  • USA
  • November 20 2017

Interestingly, it's a case that is almost a year old that has us thinking about litigation tourism post Bristol-Myers Squibb Co. v. Superior Court


Inside the Courts - An Update From Skadden Securities Litigators
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • November 5 2017

Judge Patti B. Saris denied the Bank of New York Mellon’s (BNY Mellon) motion to strike putative class representative Ashby Henderson. BNY Mellon


Amgen and Genentech Break New Ground in Avastin Biosimilar Dispute
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • October 26 2017

Amgen and Genentech have become embroiled in a novel procedural dispute relating to Mvasi, Amgen’s biosimilar of Genentech’s Avastin (bevacizumab). On


EPA Initiates Formal Regulatory Process to Roll Back Clean Power Plan
  • K&L Gates
  • USA
  • October 24 2017

On Monday, October 16, 2017, the Environmental Protection Agency ("EPA") published a Notice of Proposed Rulemaking in the Federal Register, marking


Frequent Participation in Hatch-Waxman Litigation in a Forum May Be Relevant to Whether a Defendant Can Be Sued in That Forum for Patent Infringement
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • October 19 2017

Submitting an Abbreviated New Drug Application (ANDA) and subsequent prospective infringement can be sufficient to show an act of infringement under


The Third Circuit Fosamax Preemption Error Has Got To Go, Part 2
  • Reed Smith LLP
  • USA
  • October 4 2017

We've come to expect top-flight work product from the Product Liability Advisory Council (PLAC), even when it isn't Bexis pushing the pen or pecking


The Supreme Court Interprets the Biologics Price Competition and Innovation Act in Favor of Biosimilar Applicants
  • Harris Beach PLLC
  • USA
  • October 3 2017

The Buzz, published by the American Intellectual Property Law Association featured Laura Smalley’s article on The Biologics Price Competition and